Catalog No.: PC-23813Not For Human Use, Lab Use Only.
SCR-1481B1 (Metatinib anhydrous, Compound 68) is a specific small molecule inhibitor of gasdermin D (GSDMD) targeting the GSDMD N-terminal oligomerization interface I (MST KD=0.4 uM), exert pyroptosis inhibitory effects, also shows inhibition on Met activation VEGFR.
SCR-1481B1 (Metatinib anhydrous, Compound 68) is a specific small molecule inhibitor of gasdermin D (GSDMD) targeting the GSDMD N-terminal oligomerization interface I (MST KD=0.4 uM), exert pyroptosis inhibitory effects, also shows inhibition on Met activation VEGFR. SCR-1481B1 (Metatinib anhydrous, Compound 68) significantly inhibited the release of LDH and IL-1β from iBMDM cells primed with LPS. SCR-1481B1 (Metatinib anhydrous, Compound 68) specifically inhibit GSDMD N-terminal oligomerization. SCR-1481B1 (Metatinib anhydrous, Compound 68) does not affect the cytotoxicity induced by GSDME N-terminal fragment and its oligomerization in HEK293T cells. SCR-1481B1 (Metatinib anhydrous, Compound 68) specifically blocks GSDMD-mediated pyroptosis downstream of inflammasome activation. SCR-1481B1 (Metatinib anhydrous, Compound 68) (10 mg/kg) significantly alleviate mouse sepsis in murine model of sepsis. Combination SCR-1481B1 (Metatinib anhydrous, Compound 68) and PD-L1 antibody significantly enhances anti-tumor efficacy.
Physicochemical Properties
M.Wt
821.12
Formula
C32H40ClF2N6O13P
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
3(4H)-Pyridinecarboxamide, N-[4-[(2-amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-5-(4-fluorophenyl)-4-oxo-1-[(phosphonooxy)methyl]-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:2)
References
1. Hu Y, et al. Cell Chem Biol. 2024 Dec 19;31(12):2024-2038.e7.
